Comparison of the induction of P-glycoprotein activity by nucleotide, nucleoside, and non-nucleoside reverse transcriptase inhibitors

European Journal of Pharmacology

Volumn 579, Issue 1-3, 2008, Pages 104-109

  Weiss, Johanna ^a   Weis, Nicola ^a   Ketabi Kiyanvash, Nahal ^a   Storch, Caroline H ^a   Haefeli, Walter E ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Drug interactions; Induction; NNRTIs (non nucleoside reverse transcriptase inhibitors); NRTIs (nucleoside reverse transcriptase inhibitors); NtRTI (nucleotide reverse transcriptase inhibitor); P glycoprotein

Indexed keywords

ABACAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; GLYCOPROTEIN P; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE; NUCLEOSIDE; NUCLEOTIDE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN FUNCTION;

ADENINE; ANTI-HIV AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; NUCLEOSIDES; NUCLEOTIDES; P-GLYCOPROTEIN; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; UP-REGULATION;

EID: 37549018985     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.11.007     Document Type: Article

References (42)

1. Albermann N., Schmitz-Winnenthal F.H., Z'graggen K., Volk C., Hoffmann M.M., Haefeli W.E., and Weiss J. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem. Pharmacol. 70 (2005) 949-958
2. Antoniou E., and Tseng A.L. Interactions between antiretrovirals and antineoplastic drug therapy. Clin. Pharmacokinet. 44 (2005) 111-145
3. Back D., Gibbons S., and Khoo S. An update on therapeutic drug monitoring for antiretroviral drugs. Ther. Drug Monit. 28 (2006) 468-473
4. Breuninger L.M., Paul S., Gaughan K., Mik T., Chan A., Aaronson S.A., and Kruh G.D. Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res. 55 (1995) 5342-5347
5. Chandler B., Almond L., Ford J., Owen A., Hoggard P., Khoo S., and Back D. The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on P-glycoprotein expression in peripheral blood mononuclear cells in vitro. JAIDS 33 (2003) 551-556
6. Dantzig A.H., Shepard R.L., Law K.L., Tabas L., Pratt S., Gillespie J.S., Binkley S.N., Kuhfeld M.T., Starling J.J., and Wrighton S.A. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J. Pharmacol. Exp. Ther. 290 (1999) 854-862
7. Dasgupta A., and Okhuysen P.C. Pharmacokinetic and other drug interactions in patients with AIDS. Ther. Drug Monit. 23 (2001) 591-605
8. De Maat M.M.R., Ekhart G.C., Huitema A.D.R., Koks C.H.W., Mulder J.W., and Beijnen J.H. Drug interactions between antiretroviral drugs and comedicated agents. Clin. Pharmacokinet. 42 (2003) 223-282
9. De Moerloose B., Dhooge C., and Phillippe J. Discordance of P-glycoprotein expression and function in acute leukaemia. Adv. Exp. Med. Biol. 457 (1999) 107-118
10. Faucette S.R., Zhang T.C., Moore R., Sueyoshi T., Omiecinski C.J., LeCluyse E.L., Negishi M., and Wang H. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J. Pharmacol. Exp. Ther. 320 (2007) 72-80
11. Feller N., Kuiper C.M., Lankelma J., Ruhdal J.K., Scheper R.J., Pinedo H.M., and Broxterman H.J. Functional detection of MDR1/P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry. Br. J. Cancer 72 (1995) 543-549
12. Flexner C. Antiretroviral agents and treatment of HIV infection. In: Brunton L.L. (Ed). Goodman and Gilman's: The pharmacological basis of therapeutics (2006), McGraw-Hill, New York 1273-1314
13. Hennessy M., Kelleher D., Spiers J.P., Barry M., Kavanagh P., Back D., Mulcahy F., and Feely J. St Johns Wort increases expression of P-glycoprotein: implications for drug interactions. Br. J. Clin. Pharmacol. 53 (2002) 75-82
14. Huang L., Wring S.A., Wooley J.L., Brouwer K.R., Serabjit-Singh C., and Polli J.W. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab. Dispos. 29 (2001) 754-760
15. Kageyama M., Fukushima K., Togawa T., Fujimoto K., Taki M., Nishimura A., Ito Y., Sugioka N., Shibata N., and Takada K. Relationship between excretion clearance of rhodamine 123 and P-glycoprotein (Pgp) expression induced by representative Pgp inducers. Biol. Pharm. Bull. 29 (2006) 779-784
16. Kliewer S.A., Goodwin B., and Willson T.M. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr. Rev. 23 (2002) 687-702
17. Lucia M.B., Cauda R., Landay A.L., Malori W., Donelli G., and Ortona L. Transmembrane P-glycoprotein (P-gp/P-170) in HIV infection: analysis of lymphocyte surface expression and drug-unrelated function. AIDS Res. Hum. Retrovir. 11 (1995) 893-901
18. Ma Q., Olanrewaju O., Smith P.F., DiCenzo R., Slish J.C., Cataranzo L.M., Forrest A., and Morse G.D. Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors. Expert Opin. Drug Metab. Toxicol. 1 (2005) 1-13
19. Matheny C.J., Ali R.Y., Yang X., and Pollack G.M. Effect of prototypical inducing agents on P-glycoprotein and CYP3A expression in mouse tissues. Drug Metab. Dispos. 32 (2004) 1008-1014
20. Meaden E.R., Hoggard P.G., Khoo S.H., and Back D.J. Determination of P-gp and MRP expression and function in peripheral blood mononuclear cells in vivo. J. Immunol. Methods 262 (2002) 159-165
21. Mouly S., Lown K.S., Kornhauser D., Joseph J.L., Fiske W.D., Benedek I.H., and Watkins P.B. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin. Pharmacol. Ther. 72 (2002) 1-9
22. Mukwaya G., MacGregor T., Hoelscher D., Heming T., Legg D., Kavanaugh K., Johnson P., Sabo J.P., and McCallister S. Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers. Antimicrob. Agents Chemother. 49 (2005) 4903-4910
23. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents (2006), Department of Health and Human Services 1-113 May 4
24. Paul S., Beruninger L.M., and Kruh G.D. ATP-dependent transport of lipophilic cytotoxic drugs by membrane vesicles prepared from MRP-overexpressing HL60/ADR cells. Biochemistry 35 (1996) 14003-14011
25. Perloff M.D., von Moltke L.L., Marchand J.E., and Greenblatt D.J. Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. J. Pharm. Sci. US 90 (2001) 1829-1837
26. Perloff E.S., Duan S.X., Skolnik P.R., Greenblatt D.J., and von Moltke L.L. Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab. Dispos. 33 (2005) 764-770
27. Peters T., Lindenmaier H., Haefeli W.E., and Weiss J. Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein. Naunyn-Schmiedeberg's Arch. Pharmacol. 372 (2006) 291-299
28. Piscitelli S.C., and Gallicano K.D. Interactions among drugs for HIV and opportunistic infections. New Engl. J. Med. 344 (2001) 984-986
29. Piscitelli S.C., Burstein A.H., Chaitt D., Alfaro R.M., and Falloon J. Indinavir concentrations and St John's Wort. Lancet 355 (2000) 547-548
30. Sankatsing S.U.C., Beijnen J.H., Schinkel A.H., Lange J.M.A., and Prins J.M. P-glycoprotein in human immunodeficiency virus type 1 infection and therapy. Antimicrob. Agents Chemother. 48 (2004) 1073-1081
31. Schuetz E.G., Beck E.T., and Schuetz J.D. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol. Pharmacol. 49 (1996) 311-318
32. Shepard R.L., Cao J., Starling J.J., and Dantzig A.H. Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979. Int. J. Cancer 103 (2003) 121-125
33. Signoretti C., Romagnoli G., Turriziani O., Antonelli G., Dianzani F., and Cianfruglia M. Induction of the multidrug-transporter P-glycoprotein by 3′-azido-3′-deoxythymidine (AZT) treatment in tumor cell lines. J. Exp. Clin. Cancer Res. 16 (1997) 29-32
34. Smith P.F., DiCenzo R., and Morse G.D. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin. Pharmacokinet. 40 (2001) 893-905
35. Staudinger J.L., Madan A., Carol K.M., and Parkinson A. Regulation of drug transporter gene expression by nuclear receptors. Drug Metab. Dispos. 31 (2003) 523-527
36. Storch C.H., Theile D., Lindenmaier H., Haefeli W.E., and Weiss J. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem. Pharmacol. 73 (2007) 1573-1581
37. Stormer E., von Moltke L.L., Perloff M.D., and Greenblatt D.J. Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm. Res. 19 (2002) 1038-1045
38. Timsit Y.E., and Neghishi M. CAR and PXR: the xenobiotic-sensing receptors. Steroids 72 (2007) 231-246
39. Wang H., and LeCluyse E.L. Role or orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin. Pharmacokinet. 42 (2003) 1221-1351
40. Xu C., Li C.Y., and Kong A.N. Induction of phase I, II, and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res. 28 (2005) 249-268
41. Zhou S., Yung Chan S., Cher Goh B., Chan E., Duan W., Huang M., and McLeod H.L. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet. 44 (2005) 279-304
42. Zisowsky J., Koegel S., Leyers S., Devarakonda K., Kassack M.U., Osmak M., and Jaehde U. Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells. Biochem. Pharmacol. 73 (2007) 298-307